免疫联合治疗尿路上皮癌的阴性数据月底发表

药组和治疗法单药组中会极小也就是说3级的治疗法关的过敏赴援共五17%和72%。

03

精 惑 交 论

本精惑成叶确认，在以铌类为普础的队内治疗法建议书中会转至帕姆唑并不必特别是在改善中会期尿路上皮癌病患者的无传染病肉食动物期和总肉食动物期，因此不推荐相当多引入中会期尿路上皮癌的治疗法。而且，帕姆唑治疗法效用与PD-L1的暗示量没有显着的关的性。

参考文献

1. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 12 30986. J Clin Oncol. 2012; 30: 191–99.

2. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 14 376: 1015–26.

3. Galsky MD, Arija JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395: 1547–57.

4. Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18: 1483–92.

5. Galsky MD, Mortazi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020; 38: 1797–806.

6. Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21: 1574–88.

。

肚子痛拉肚子怎么缓解
消除眼疲劳用什么眼药水好
骨关节炎吃什么药好
如何让脸色红润有光泽
慢性结膜炎如何治疗
非酒精性脂肪肝怎么治疗
视觉疲劳怎么缓解
慢性腹泻吃什么益生菌效果好